Acadian Asset Management’s Satsuma Pharmaceuticals, Inc. Common Stock STSA Stock Holding History

Acadian Asset Management’s Portfolio STSA Stock Details STSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-275,069	Closed	-$191K	–	1964
2023 Q1	$191K	Hold	275,069	–	–	﹤0.01%	1264
2022 Q4	$246K	Buy	+275,069	New	+$797K	﹤0.01%	1232
2021 Q4	–	Sell	-5,253	Closed	-$24K	–	1896
2021 Q3	$24K	Buy	5,253 +517	+11%	+$2.74K	﹤0.01%	1648
2021 Q2	$33K	Buy	+4,736	New	+$25.5K	﹤0.01%	1871
2021 Q1	–	Sell	-29,618	Closed	-$137K	–	2394
2020 Q4	$137K	Buy	29,618 +19,804	+202%	+$85.4K	﹤0.01%	1660
2020 Q3	$38K	Buy	+9,814	New	+$197K	﹤0.01%	1930

Acadian Asset Management's STSA Position: Q2 2023 in Review

Acadian Asset Management sold out of Satsuma Pharmaceuticals, Inc. Common Stock (STSA) in Q2 2023, closing a stake of 275,069 shares — an estimated $191K sold.

Acadian Asset Management first reported a position in STSA in Q3 2020 and held it in 6 quarters. The position peaked at $246K in Q4 2022. 0 funds tracked by Wall St. Rank hold STSA as of Q2 2023.

Acadian Asset Management reported no remaining Satsuma Pharmaceuticals, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Acadian Asset Management sold 275,069 Satsuma Pharmaceuticals, Inc. Common Stock shares in Q2 2023, an estimated $191K.
Acadian Asset Management first reported a position in Satsuma Pharmaceuticals, Inc. Common Stock in Q3 2020 and held it in 6 quarters.
Acadian Asset Management's Satsuma Pharmaceuticals, Inc. Common Stock position peaked at $246K in Q4 2022.
0 funds tracked by Wall St. Rank held Satsuma Pharmaceuticals, Inc. Common Stock as of Q2 2023.

Based on Acadian Asset Management's 13F filing for Q2 2023, filed 7 Aug 2023.